In this study, KRAS mutation status (mutated yes/no) was not significantly associated with reduced OS or PFS benefit of FTD/TPI versus placebo; however, codon-specific analyses were not performed3,4. The gene discussed is KRAS; the disease is frontotemporal dementia.